Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine Hospital
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 750
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
AML in adults represents a group of heterogeneous diseases; the prognosis remains poor despite significant therapeutic advances in recent years. In order to optimize patient care, it is necessary to have "real life" data that exhaustively reports on the patients treated in our department. The objective of this study is:
- To describe the AML treated within the hematology department
- To optimize the management of patients with AML.
详细描述
Current state of knowledge:
Acute myeloblastic leukemia are the most common leukemias in adults. This pathology is very heterogeneous. It has a poor prognosis despite numerous therapeutic advances. The lack of randomized clinical trials can make certain treatment decisions difficult. In addition, patients with comorbidities or the elderly are most often excluded from these trials even though they represent a significant proportion of new diagnoses.
Objectives:
Primary objective Evaluate the overall survival of adult patients treated for AML in our hematology department at Saint-Antoine Hospital.
Secondary objectives
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age :18 years and older
- •Patients with AML
- •Non objection to research
排除标准
- •Minor patients
- •Acute promyelocytic leukemia (AML3)
结局指标
主要结局
Overall survival
时间窗: 2 years after diagnosis
次要结局
- Incomplete cytological remission rate(after the phase of induction up to 24 months)
- Side effects(24 months)
- Cytological remission rate(after the phase of induction up to 24 months)
- Leukemia free survival rate(24 months)
- the rate of patients receiving intensive treatment(24 months)
- Overall survival(1 year after diagnosis)